• For fast subcutaneous injection: <1 to >10 ml
  • Injection with limited dexterity requirements (no need for hand holding or fine motor skills)
  • Attach to skin – pre-filled – using a glass cartridge

<1 ml

<3 ml

<10 ml

Benefits of Hands-Free Autoinjector

Injection volumes from < 1 ml to > 10 ml

Use related

  • No need to hold injector steady
  • Can be operated without fine motor skills
  • Option to use smaller needle diameters
  • Automatic needle insertion/retraction

Technically

  • Fully mechanical & spring driven (no electronics)

  • Low complexity

  • Flow rate configurable

  • Based on proven primary packaging
    – Commercially available glass cartridges with standard septa
    – Commercially available plungers

  • IP protected

Why Hands-Free Autoinjectors

  • Absorption enhancers allow for subcutaneous injection of larger volumes at higher flow rates (with autoinjectors or pre-filled syringes)

  • Current larger volume injection options are not always ideal:
    – Hand-held autoinjectors/pre-filled syringes may require a steady hold for a longer period of time
    – In order to reduce hold time, larger needles may be required

  • People with dexterity challenges prefer a hands-free solution even for injection of <1 ml*

* Proprietary data from user preference studies demonstrate  preference for Hand-Free Autoinjector among Rheumatoid Arthritis (RA) patients  – even for low volume injection of adalimumab

Sequence of use/functionality

Intended as pre-filled, pre-loaded and ready to use

Stick to the skin via adhesive patch

Needle shield prevents premature activation

One button operation

Activate injection with finger or heel of hand

Automatic needle retraction at end of dose

Visual, audible and tactile end of dose signal

After use: detach from skin and discard

Needle shield prevents finger stick in case of e.g. premature removal

Pre injection

During injection

Post injection

Development stage

The concept is ready for regulatory development, feasibility evaluation and user studies

  • 3 ml demo device implemented in moulded parts
  • 0.8 ml and 10 ml available as functional demo devices (machined/3D printed)

Collaboration

TJCC-Subcuject is seeking to out-license/divest IP to pharmaceutical- or device companies pursuing development of patient friendly combination solutions

Jesper Roested
CEO
Phone: +45 2122 7772
jesper@roested.dk

TJCC-Subcuject ApS
Olesvej 14
DK-2830 Virum
Denmark
VAT no: DK-4488809

Management

Jesper Roested

CEO
20+ years experience in business development, management and venture financing within medtech and life sciences. MSc. In Medical Electronics & Physics. Previously Partner at VF Venture investing in- and development of medtech companies. CEO of DDD-Diagnostic (nuclear medicine scanners), multiple positions at Novo Nordisk (in drugs and devices) and McKinsey & Co.

Claus Schmidt Møller

Inventor
B. Sc. Mechanical Engineering. 20+ years of track record in innovation of drug delivery devices. Inventor of Novopen 4 & 5 and co-inventor of Flexpen and Flextouch for Novo Nordisk. Several inventions of various medical devices made for or licensed to major Pharma and drug delivery companies. Mentioned as inventor or co-inventor on 60+ patent families.

Tomas Gundberg

Design and test engineer
Design and test engineer with more than 20 years of experience and with own development toolshop. Previous involvement in development of a large number of innovative medical devices including infusion sets and patch pumps.

Claus Demant

Extensive international experience in sales, business development and leadership from Consumer Tech & Healthcare Industries. Executive MBA, from CBS-SIMI. Global Business Development in Bang & Olufsen and European Regional Director position for Business Development at Novo Nordisk (Obesity). Mentor for startups at DTU Science Park and co-founder of several new companies